Boditech Med Inc. (KOSDAQ: 206640) - Deep Dive Research Report

Prepared 2026-06-09. All figures in Korean won (KRW) unless stated. No valuation, price, or market-cap data for the subject company appears in this report by design.

Section 1: What the Company Does

Boditech Med makes the small bench-top machines, and the disposable test cartridges that feed them, that let a doctor draw a drop of a patient's blood and get a lab-quality answer in the room, in about 10-15 minutes, instead of sending the sample to a central laboratory and waiting a day. This is called point-of-care testing (POCT). The company is based in Chuncheon, Gangwon Province, South Korea, and it sells its own branded analyzers and reagents into roughly 120 countries.

The mechanism is worth understanding because it is the whole business. A patient's finger is pricked or a small blood sample is taken. That sample is dropped into a sealed, single-use plastic cartridge that already contains every chemical reagent the test needs. The cartridge is slotted into a Boditech reader. Inside, the blood mixes with antibodies that are tagged with a fluorescent dye and are designed to grab one specific target molecule, a biomarker, such as a cardiac protein that spikes during a heart attack, a thyroid hormone, an inflammation marker like CRP, or a diabetes indicator like HbA1c. A semiconductor laser inside the reader shines light on the cartridge, the captured fluorescent tags glow, and the machine measures how brightly. More glow means more of the biomarker. The number is on the screen minutes later. Boditech calls the underlying method fluorescence immunoassay, and it has built its entire product line on it since 1998.

The company was founded in November 1998 in Chuncheon by Eui-Yul Choi, a biotechnology researcher, together with a group of fellow academics, specifically to commercialize fluorescence-based diagnostic readers and the kits that run on them. Choi remains co-founder and CEO almost three decades later, which matters for how the business is run: this is a founder-led, research-rooted company that has compounded a single core technology into an ever-wider menu of tests rather than chasing acquisitions or pivots. Over that time it has developed assays for roughly 85-90 biomarkers, and it built the capability to run those tests on whole capillary blood (the finger-prick kind), venous blood, and plasma, which is what makes the platform usable in a clinic, a pharmacy, or a field setting rather than only in a hospital lab.

"Diabetes management is most effective when the disease is detected and managed at the prediabetes stage rather than after onset... Based on our immunoassay technology, we will continue expanding our diagnostic portfolio." - Eui-Yul Choi, CEO

That sentence captures the strategy in miniature: one core platform technology, an ever-expanding test menu hung off it, sold to the part of the healthcare system that sits closest to the patient. The value proposition to a customer is speed and decentralization. A small clinic in Jakarta, a pharmacy in Riyadh, or a rural hospital in Brazil that cannot afford or justify a large Roche or Abbott central-lab analyzer can put a Boditech AFIAS or ichroma machine on the counter, run a broad menu of tests on the spot, and treat the patient in the same visit. The hard part is not any single test; it is having a deep, validated, regulator-approved menu running reliably on a cheap, rugged reader, and having built the distribution to place those readers in 120 countries.

Section 2: Business Segments

Boditech does not report in the way a conglomerate does; it is effectively a single-business company - immunoassay-based in-vitro diagnostics (IVD). However, management consistently discusses the business along two axes that function like segments, and understanding both is essential.

By revenue type: Instruments vs. Reagents (the razor-and-blade engine)

The first axis is the classic consumables model. Boditech sells two things: the analyzers (the "razor") and the disposable test cartridges/reagents (the "blades").

• Instruments are the AFIAS and ichroma family of readers. These are sold, or in many markets effectively placed, to clinics, pharmacies and hospitals. The company tracks instrument placements obsessively because each installed reader is an annuity: it can only run Boditech cartridges. Management reported a quarterly record of 3,444 new AFIAS/ichroma installations in Q1 2026 (Q1 2026 results, May 8 2026), and over 3,200 systems including more than 2,000 ichroma/AFIAS units in Q1 2025 (Q1 2025 results, May 8 2025). The installed base is the growth flywheel.

• Reagents/consumables are the high-margin recurring half. Once a reader is in the field, every test consumes a cartridge. This is the cash engine and the reason management cares about installations: each new placement compounds future reagent pull-through. The breadth of the reagent menu (cardiac, diabetes, thyroid, inflammation, fertility, vitamin D, anemia, infectious disease) is the competitive moat because it determines how much a single placed instrument is used.

This is why the company behaves like a consumables business even though headlines focus on revenue: the strategic priority is always to grow the installed base of readers, because reagent revenue follows it with a lag and a high margin.

By disease/menu category

The second axis is the test menu itself, which management breaks down by disease area and which reveals where growth is coming from:

• Cardiovascular (cardiac markers such as troponin, NT-proBNP, D-dimer): a foundational, high-volume category; grew 16.1% YoY in Q2 2025 (Q2 2025 results).
• Diabetes (HbA1c and related): grew 13.2% YoY in Q2 2025; tied to the CEO's stated prediabetes-screening push.
• Infectious disease: the legacy strength, inflated during COVID and now a smaller, normalized share. Management has deliberately pivoted the mix toward non-infectious lines.
• "Other" disease areas (vitamin D, anemia/Hemochroma, hormones, fertility, autoimmune): the fastest-growing bucket, up 49.5% YoY in Q2 2025 and over 140% across full-year 2025 (FY2025 results). Vitamin D has been growing >30% annually and the Hemochroma anemia line ~46% annually.

The strategic story management tells is the rotation away from infectious-disease dependence and toward a balanced, non-infectious chronic-disease menu sold into emerging markets. That rotation is the segment-level narrative that runs through all five reporting periods.

Section 3: Products and Business Detail

The instrument catalogue (the readers)

• ichroma II - the workhorse. A compact, easy-to-use single-cartridge fluorescence POCT analyzer for cardiac, cancer, hormone, infectious, autoimmune and metabolic markers. It is the product that put Boditech in 120 countries and remains the volume backbone in price-sensitive markets.
• ichroma III - a higher-throughput successor enabling simultaneous multi-parameter testing.
• ichroma M2 / M3 - portable, smaller-footprint analyzers for the most decentralized settings (pharmacies, mobile clinics).
• AFIAS-1 / AFIAS-3 / AFIAS-6 - the more automated, "sample-to-answer" family. AFIAS-1 is a single-channel lateral-flow platform with all-in-one cartridges; AFIAS-3 runs three independent channels simultaneously; AFIAS-6 is an integrated six-parallel-test system for higher-throughput settings. AFIAS represents the move upmarket from single-test convenience toward small-lab-replacement capability.
• ichroma-50 - an automated, high-throughput immunoassay system for larger labs.
• Hemochroma PLUS - a handheld hemoglobin/anemia analyzer that runs a finger-prick sample through a disposable cuvette. A distinct razor in its own right with its own fast-growing reagent stream.
• ExAmplar / ExAmplar II - a compact real-time PCR molecular system using ready-to-use cartridges to detect viruses/bacteria, paired with NuActor, an automated nucleic-acid extraction system. This is Boditech's foothold in molecular diagnostics, extending it beyond immunoassay.
• TRIA - a newer high-sensitivity immunoassay platform positioned for advanced/ultra-sensitive assays.

The reagent catalogue (the blades)

The menu spans roughly 85-90 biomarkers across cardiac (troponin I, NT-proBNP, D-dimer, CK-MB), inflammation (CRP, PCT), diabetes (HbA1c), thyroid and hormones (TSH, T3/T4, hormone panels, fertility/beta-hCG), vitamin D ("Vitamin D Neo," runnable on whole blood, serum or plasma), anemia (Hemochroma), tumor markers, autoimmune markers, and infectious-disease assays. The strategic point is menu depth: a placed AFIAS-6 that can run cardiac, diabetes, thyroid, CRP and vitamin D from one box is far stickier and more utilized than a single-test device.

Technology, manufacturing and certifications

The hard-to-replicate asset is the integration of three things: (1) the fluorescence-immunoassay chemistry and the antibody pairs for each of ~90 markers, each individually developed and validated; (2) the manufacturing of consistent, sealed, dry-reagent cartridges at scale and at low cost; and (3) the regulatory dossier for each assay in each market. A diagnostic reagent is a regulated medical device; selling it requires approvals (CE marking under the EU's IVDR, national registrations across MENA, Latin America, Asia, and Korea's MFDS). Building approvals for ~90 assays across ~120 countries is a multi-decade compounding effort that a new entrant cannot shortcut. Manufacturing is concentrated at the Chuncheon, Korea base.

Geographies and milestones

Boditech is overwhelmingly export-driven; the large majority of revenue is sold outside Korea. Key regional roles as disclosed across the 2025 reporting periods:

• MENA (Middle East & North Africa) - the single largest region, ~25-25.5% of sales, growing 29-40% YoY. The core engine.
• Europe - ~23% of revenue, recovering (Q2 2025 +5.9%) and an explicit Q1 2026 growth driver including new-market entries.
• Latin America - fast-growing (Q2 2025 +38.6%; FY2025 cited >100% recovery in previously weak Africa/LatAm markets).
• Asia and Korea (domestic) - Q1 2026 specifically called out rising domestic in-clinic testing demand.

Milestones that shaped the business: founding on fluorescence technology in 1998; the ichroma platform reaching 100+ countries; a COVID-era infectious-disease revenue spike (Q3 2024 was cited as record sales since the COVID endemic transition) followed by a deliberate rebalancing toward non-infectious lines; the move into molecular diagnostics (ExAmplar); and the 2025 announced entry into veterinary diagnostics via OEM supply deals and direct entry targeting the US and Europe.

Section 4: Customers

The end customers are the decentralized edges of healthcare systems: small and mid-size clinics, primary-care physicians' offices, pharmacies, hospital emergency and outpatient departments, and in emerging markets, standalone testing centers and field/mobile clinics. Geographically the customer base is concentrated in MENA, Europe, Latin America, and Asia, with a growing domestic Korean in-clinic base.

The buying decision is almost never made by Boditech selling directly to a clinic in, say, Algeria. The customer that actually matters most is the in-country distributor. Boditech's model is to sign distributors who hold the local regulatory registrations, place the analyzers with clinics, and reorder cartridges. The clinic's clinician chooses based on test menu breadth, time-to-result, accuracy versus the central lab, and reagent cost per test. The distributor chooses based on margin, menu, regulatory support, and reliability of supply. This two-layer structure is why management talks in terms of regional growth and installations rather than named accounts.

Switching costs are real and they operate at the instrument level. Once a clinic installs an AFIAS or ichroma reader, that box only runs Boditech cartridges; switching to Quidel or Abbott means buying a new analyzer, re-training staff, and re-validating workflows. The deeper the menu the clinic uses on that one box, the higher the lock-in. At the distributor level, switching is harder still: a distributor that has invested years obtaining national registrations for dozens of Boditech assays has a sunk regulatory asset it will not lightly abandon. This is the closest thing the business has to a moat - not patents, but installed-base lock-in multiplied by regulatory inertia.

Concentration appears to be low at the customer level and moderate at the geographic level. No single distributor or country dominates in the way a single OEM customer would dominate a components supplier; the largest single region (MENA) is ~a quarter of sales. The flip side is that revenue is exposed to emerging-market macro and FX volatility rather than to one big account. Contract structure is largely recurring reagent reorder flow layered on one-time instrument sales - the consumables half gives reasonable revenue predictability, while instrument sales are lumpier and tied to distributor expansion campaigns.

Section 5: Competitive Landscape

The diagnostics industry is dominated at the top by a handful of giants - Roche, Abbott, Siemens Healthineers, Danaher, and BD - who together control most of the global IVD and point-of-care market (the top five POC vendors held roughly 60% of share in 2024). But Boditech does not compete head-on with these companies in their core territory of large central-laboratory analyzers in wealthy-country hospitals. Boditech competes in a specific niche: affordable, broad-menu fluorescence POCT for clinics and pharmacies, primarily in emerging markets. That positioning is what keeps it alive and growing in the shadow of giants.

Where Boditech wins: price, menu breadth on a single cheap box, ruggedness for decentralized settings, and a distribution network painstakingly built across ~120 emerging and mid-tier markets where the majors are less aggressive. Where Boditech loses: in developed-market hospitals and reference labs, where Roche/Abbott/Siemens own the relationships, the connectivity/IT integration, the brand trust, and the high-end immunoassay performance; and against Abbott specifically in handheld cardiac/blood-gas (i-STAT) and broad POC (Afinion). Boditech is a price-and-access player, not a technology-frontier player.

Within its own niche the direct competitors are the other POC immunoassay specialists - Quidel (Sofia/Triage), Radiometer (Danaher's AQT90 FLEX), Abbott Afinion, Eurolyser, Response Biomedical, and Nova Biomedical - plus Korean diagnostics peers that share the emerging-market export model.

Barriers to entry are moderate-to-high but not absolute. The barrier is not a single patent; it is the cumulative regulatory dossier (~90 assays × ~120 countries), the validated antibody library, and the distributor network - all of which take a decade-plus to assemble. A well-funded new entrant can build a reader; it cannot quickly replicate a registered menu and a placed installed base. The structural risk is from below, not above: low-cost Chinese IVD manufacturers (e.g., Getein, Wondfo) pursuing the same emerging-market POCT niche with similar price points, which could commoditize the category over time.

(Market caps shown solely as peer-size references, not applied to the subject company.)

Section 6: Industry

Demand for point-of-care diagnostics is driven by a few durable forces: the global push to decentralize testing out of central labs and closer to the patient; aging populations and the rising burden of chronic disease (cardiovascular, diabetes); the build-out of basic healthcare infrastructure across emerging markets where central labs are scarce; and, since COVID, a structurally elevated comfort with rapid on-site testing. For Boditech specifically, the emerging-market clinic and pharmacy build-out is the key tailwind because that is exactly where it sells.

On size, the broad point-of-care diagnostics market is large and growing - estimates put it around US$55-60 billion in 2026, compounding at roughly 9-10% annually toward US$90+ billion by the early 2030s (Mordor Intelligence; GM Insights; Coherent Market Insights). The narrower immunoassay analyzers market is estimated around US$7+ billion (Grand View Research). Boditech is a small player in the total POC pool but a meaningful one in the affordable emerging-market immunoassay sub-niche.

Boditech sits in the middle of the supply chain: it sources raw antibodies and components, manufactures finished readers and cartridges in Korea, and sells through distributors to end clinics. It is not import-dependent for its core product in the way a pure distributor would be; it is a manufacturer-exporter, which is the more defensible position. The relevant import-substitution dynamic runs the other way - Boditech is itself the import-substituting, lower-cost alternative to Western majors in many of its markets, and it in turn faces the threat of cheaper Chinese substitutes.

The regulatory environment is the defining feature of the industry. Every assay is a regulated medical device requiring market-by-market approval - CE marking under the EU IVDR (whose tightened requirements raised the compliance bar for all players), Korea's MFDS, and dozens of national registrations across MENA, Latin America and Asia. This regulation is simultaneously a cost and a moat: it slows Boditech's expansion but also walls out casual entrants.

Cyclicality is relatively low at the demand level - diagnostic testing is non-discretionary healthcare - but Boditech's reported results carry two specific swings: the post-COVID normalization of infectious-disease testing (a headwind it has been absorbing and offsetting with non-infectious growth), and emerging-market FX/macro volatility, since the bulk of revenue is earned in dozens of foreign currencies. Industry-level tailwinds: decentralization, chronic-disease screening, EM healthcare build-out. Industry-level headwinds: IVDR compliance cost, pricing pressure from low-cost Asian entrants, and the fading of the COVID testing bubble.

Section 7: Growth Triggers

Extracted from the five most recent reporting-period disclosures (Q1 2025 through Q1 2026). Boditech does not hold English earnings calls; these are drawn from its quarterly results releases.

• European market expansion and new-market entries. Europe was named the explicit growth driver in the most recent quarter, including expansion into new European markets. (Q1 2026 results, May 8 2026 - repeated theme; Europe also flagged recovering in Q2 2025.)

  "...growing domestic in-clinic testing demand and expansion into new European markets contributing to continued growth." (Q1 2026 results)

• Record instrument installations driving future reagent pull-through. A quarterly-record 3,444 new AFIAS/ichroma installations in Q1 2026, building on >3,200 in Q1 2025. Each placement seeds future consumables revenue. (Q1 2026 results, May 8 2026; Q1 2025 results, May 8 2025 - repeated theme.)

• Rising domestic (Korea) in-clinic testing demand. Newly emphasized as a contributor in the most recent quarter, a shift from the historically export-dominated story. (Q1 2026 results, May 8 2026 - new.)

• MENA as the core growth engine. MENA grew 29-40% YoY across 2025 and is ~25% of sales; management treats it as the primary regional driver. (Q2 2025 and FY2025 results - repeated across multiple periods.)

• Latin America and Africa recovery. Previously weak Africa/LatAm markets posted >100% growth in FY2025; LatAm +38.6% in Q2 2025. (Q2 2025 results; FY2025 results - repeated.)

• Non-infectious "other disease" menu surge. Vitamin D, anemia (Hemochroma), and other chronic/wellness markers grew >140% in FY2025 and +49.5% in Q2 2025, diversifying the mix away from infectious disease. (Q2 2025 results; FY2025 results - repeated.)

• Veterinary diagnostics market entry. Management stated 2025 would mark the first step into veterinary diagnostics through OEM supply agreements with global distributors and direct entry, targeting the US and Europe. (FY2024/2025 management commentary - new optional line.)

  "2025 will mark the first step in expanding into the veterinary diagnostics market through OEM supply agreements... with target markets including the United States and Europe." (CEO commentary)

• Diabetes/prediabetes screening push. The CEO has tied portfolio expansion to early diabetes/prediabetes detection; diabetes assays grew 13.2% in Q2 2025. (Q2 2025 results + CEO commentary - repeated theme.)

Section 8: Key Risks

• Emerging-market and FX concentration. The large majority of revenue is earned across ~120 mostly emerging-market countries and dozens of currencies, with MENA alone ~25%. The mechanism: a sharp KRW appreciation, or macro/currency stress in MENA or Latin America, directly compresses reported revenue and can stall distributor reorders. This is a high-probability moderate drag rather than a catastrophic risk - it is the normal weather of the business, visible in the regional growth swings disclosed each quarter.

• Low-cost Chinese competition commoditizing the niche. Boditech's defensibility is "good-enough menu at a low price for emerging markets." Chinese IVD manufacturers (Getein, Wondfo and others) target the identical niche with similar economics. The mechanism: price-based share erosion and reagent-margin compression in exactly the price-sensitive markets Boditech depends on. Moderate probability, potentially structural if it accelerates - this is the most serious long-term threat to the model.

• Post-COVID infectious-disease normalization. Infectious-disease testing was inflated during COVID; its normalization is an ongoing headwind that management has been offsetting with non-infectious growth. The risk is that if the non-infectious "other disease" surge (vitamin D, anemia) decelerates, the infectious-disease drag becomes visible in headline growth. Management's own framing of pivoting toward a "balanced portfolio" (Q3 2025) is implicit acknowledgment of this exposure.

• Distributor-dependency and channel risk. Boditech reaches clinics through in-country distributors who hold the registrations. The mechanism: loss of, or underperformance by, a key regional distributor can stall an entire country's revenue, and Boditech has limited direct control over end-customer relationships. Moderate probability, contained in impact because no single distributor dominates.

• Regulatory burden (IVDR and registrations). Each assay needs market-by-market approval; the EU's tightened IVDR raised compliance costs. The mechanism: delays or failures in re-certifying the menu under stricter rules can freeze European growth - notable given Europe is ~23% of sales and the named growth driver. A high-probability cost drag, low-probability acute disruption.

• Operating-margin softness despite revenue growth. In Q2 2025 operating profit was roughly flat (-0.7% YoY) even as revenue rose 14.5%, and FY2024 operating profit fell 7.6% on higher revenue. The mechanism: instrument-led growth (placing cheap readers to seed future reagent sales) and channel/expansion spending can dilute near-term margin even when the top line grows. A real, observable tension in the numbers - growth is being partly bought with margin.

• Founder/key-person concentration. Eui-Yul Choi has run the company since 1998 and is the strategic center of gravity. Low-probability but high-impact if succession is not managed.

Section 9: Walk the Talk

The five reporting periods used: Q1 2025 (May 8 2025), Q2 2025 (Aug 2025), Q3 2025 (Nov 2025), FY2025/Q4 2025 (Feb 2026), and Q1 2026 (May 8 2026). The most recent is within ~30 days of today. Because Boditech does not hold English earnings calls, this assessment cross-references the quarterly results disclosures and CEO commentary rather than call transcripts.

Starting with Q1 2025, management presented a story of accelerating, profitable growth: revenue up 18% YoY to ₩39.1B and operating profit up 37% to ₩8.1B, a 20.7% operating margin, with MENA up >40% and over 3,200 instrument placements. The implicit guidance was that the non-infectious, emerging-market, installation-led model was working and would continue.

By Q2 2025, the top-line promise held - revenue ₩41.5B, +14.5% YoY, and sequential acceleration with margin improving to 22.2%. But a crack appeared that management was candid about: operating profit was essentially flat YoY (-0.7%) despite double-digit revenue growth. The regional and menu diversification thesis was delivering exactly as described - MENA +29.3%, LatAm +38.6%, Europe recovering +5.9%, and the non-infectious "other" category +49.5%. So the growth narrative was being met precisely; the margin narrative was where reality lagged the Q1 optimism.

By Q3 2025, the cumulative nine-month picture (₩120.5B, +12.7%) confirmed steady mid-teens growth, and management reframed the story around a "balanced portfolio" with non-infectious lines and emerging markets carrying the load. This was consistent, not erratic - the same diversification thesis, now described as achieved rather than aspirational. Notably, management also acted on capital return here: the ₩5B buyback authorized August 27 2025 was substantially executed by end-September (342,026 shares, ₩4.98B), i.e., they did what they announced, quickly.

FY2025 delivered the headline payoff: full-year revenue of ₩162B, a record, up 17.3% - actually an acceleration over the 2.9% of 2024 and validation of the emerging-market pivot. The non-infectious surge (>140%) and the >100% Africa/LatAm recovery that management had been narrating quarter by quarter showed up in the annual numbers. Management does what it says on revenue and mix.

Q1 2026 continued the pattern: revenue ₩42.8B (+9.6%), net profit up 30.1%, a record 3,444 installations, and Europe plus domestic demand as the new drivers. The growth rate moderated from the high-teens of 2025 to single digits, which is the one honest caution - the comparison base is now higher and the pace is normalizing.

The verdict: this is management that does what it says on the things it controls - revenue growth, geographic diversification, menu rotation away from infectious disease, and capital return - and is forthright about the one place reality has lagged, which is operating-margin leverage. The diversification thesis announced in early 2025 was delivered by year-end 2025. There is no pattern of dropped promises or moved goalposts. The reasonable skeptic's note is that growth is partly installation-led and margin-dilutive, and management has been transparent rather than evasive about that trade-off.

Section 10: Shareholder Friendliness Index

Dividends. Boditech pays a modest, growing cash dividend. The most recent total dividend was around ₩150 per share, with the dividend yield rising from roughly 0.89% (2024) to about 1.14% (2025) and the payout ratio increasing from ~12.1% to ~13.7% over the same period (Stockopedia; TradingView dividend data). The trend is a small, steadily rising payout off a low base - this is a company retaining the bulk of earnings to fund its installation-led growth, not a yield story. The exact three-year DPS sequence is not fully confirmable from the English-language sources available; what is verifiable is direction (rising) and that the payout ratio remains low (well under 15%), implying ample room but limited intent to lever dividends as the primary return tool.

Buybacks and dilution. This is where Boditech is more active than its dividend suggests, and the data come from two windows. (1) MoatMap's trailing ~90-day window (since 2026-03-11): zero buybacks recorded - consistent with the fact that the 2025 program had a stated validity ending 2026-02-26. (2) Older programs, via external sources: in 2024 the company ran a ~₩2B repurchase paired with a stated policy to retire 5-10% of net profit in shares annually; and on August 27 2025 the board authorized a ₩5B buyback (with Daishin Securities, valid to Feb 26 2026), of which it repurchased 342,026 shares (1.57% of shares outstanding) for ₩4,977M by September 30 2025 - i.e., essentially fully executed within roughly a month (MarketScreener buyback filings, Aug-Sep 2025). The pairing of repurchase with cancellation/retirement means the share count is being actively managed downward rather than allowed to drift up from option dilution. Net of small dilution, the buyback-and-retire policy points to a flat-to-shrinking share count over the three-year window.

Verdict: Returns Capital (modestly) - a low-but-rising dividend combined with a genuine, promptly-executed buyback-and-cancel policy that retires shares, while still prioritizing reinvestment in installed-base growth.

Section 11: Insider Activities

Boditech is listed on KOSDAQ, where insider transactions are filed to DART (Korea's electronic disclosure system) under the Officer & Major Shareholder Securities Holdings Report (임원·주요주주 특정증권등 소유상황보고서) and the 5% Rule. This is a gated venue: the DART portal and Korean aggregators are not reliably accessible to open web search, and per the data-sourcing rules for this venue, MoatMap's nightly DART scrape is the canonical source for recent insider dealing.

Per the MoatMap database block (current as of 2026-06-08), there were zero insider transactions for 206640.KQ over the trailing 12 months. No open-market purchases or sales by directors, officers, or substantial shareholders (≥5%) were recorded in the window.

Net assessment: neutral. There is no insider buying to read as a bullish conviction signal, and equally no insider selling to read as a concern. The absence of director/officer open-market activity is common for founder-controlled Korean small-caps where the founder's large stake is long-held and static. The more meaningful capital-allocation signal over the past year is at the corporate level - the company itself was the buyer, executing the ₩5B treasury-share repurchase in Q3 2025 (see Section 10) - rather than any individual insider. Net of that, insider activity is a non-signal: nothing bullish, nothing bearish.

Section 12: Scenarios

Bull case. The emerging-market healthcare build-out keeps compounding and Boditech rides it. MENA stays a 25%-of-sales engine growing double digits, while Latin America and Africa - off a low base - keep posting outsized recovery growth, and Europe's new-market entries under IVDR turn into a durable third pillar rather than a one-quarter headline. The non-infectious menu (vitamin D, anemia, hormones, diabetes) continues to outgrow the fading infectious-disease legacy, so the mix becomes structurally higher-quality and less COVID-dependent. The record pace of instrument installations seeds a swelling base of placed readers, and reagent pull-through finally tips the margin trade-off the right way, so operating leverage returns and profit growth outpaces revenue. The veterinary-diagnostics OEM bet lands a real US/Europe distribution partner and becomes a genuine new revenue line. The founder-led, single-technology focus that looked unambitious turns out to be the reason the menu and the distributor network kept deepening while rivals were distracted. In this world Boditech is the entrenched low-cost POCT standard across the emerging-market clinic, with a shrinking share count from continued buybacks.

Base case. Management delivers roughly what the last five quarters imply: mid-single-digit to low-double-digit revenue growth as the 2025 high-teens pace normalizes against tougher comparisons. MENA, Europe, and Latin America each contribute, no single region breaks out or breaks down, and the non-infectious menu keeps offsetting infectious-disease normalization so the overall mix slowly improves. Instrument installations stay healthy and reagent revenue grows steadily behind them, but operating margin stays range-bound in the low-20s% because growth continues to be partly installation-led and channel-spend-heavy. The dividend creeps up, the buyback-and-cancel policy quietly retires a little stock each year, and veterinary remains an interesting option rather than a needle-mover. Boditech remains a steadily growing, founder-run, emerging-market diagnostics exporter - unspectacular, consistent, executing on what it says.

Bear case. The threat from below materializes. Low-cost Chinese IVD makers press into the same emerging-market POCT niche with comparable menus at lower prices, and Boditech's pricing power in MENA, Africa and Latin America erodes; reagent margins compress and the installation flywheel slows as distributors defect to cheaper readers. A bout of EM currency stress or a MENA macro shock simultaneously knocks reported revenue, exposing how concentrated the geography really is. The post-COVID infectious-disease drag persists while the non-infectious "other" surge decelerates off its huge growth rates, so headline growth stalls and the flat-margin problem visible in Q2 2025 hardens into a structural ceiling. IVDR re-certification costs or delays freeze the European growth pillar just as it was being leaned on. Veterinary never scales. In this world Boditech is squeezed from above by the majors' brand and from below by Chinese price competition, left as a slow-growth niche exporter whose menu and distribution moat, while real, is no longer widening.

Section 13 (Further Reading from SemiAnalysis / Stratechery / MBI Deep Dives) is omitted: none of the three independent analysts has published coverage of Boditech Med. Their beats (semiconductors, platform strategy, and large-cap equity deep dives) do not intersect with a Korean small-cap point-of-care diagnostics manufacturer.

Sources

• Boditech Med Q1 2026 results (newsroom)
• Boditech Med Q2 2025 results (newsroom)
• Boditech Med 2024 full-year results (newsroom)
• Boditech Med Q3 2024 record sales (newsroom)
• Boditech Med product catalogue
• AFIAS-1 product page
• ichroma II product page
• hemochroma PLUS product page
• Vitamin D Neo reagent page
• Boditech Med ₩5,000M equity buyback authorization (MarketScreener)
• Boditech Med buyback tranche update Aug 27 2025 (MarketScreener)
• Boditech Med dividend/valuation data (Stockopedia)
• Boditech Med CEO interview (newsroom)
• Global POC diagnostics market size (Mordor Intelligence)
• Primary care POC diagnostics market shares (GlobeNewswire)
• Immunoassay analyzers market size (Grand View Research)
• QuidelOrtho market cap (companiesmarketcap)
• Roche market cap (companiesmarketcap)

I've delivered the full report. A few notes on sourcing and limitations:

• Reporting periods used (5): Q1 2026 (May 8 2026), FY2025/Q4 2025 (~Feb 2026), Q3 2025 (~Nov 2025), Q2 2025 (~Aug 2025), Q1 2025 (May 8 2025). Boditech does not host English earnings calls, so its quarterly newsroom results disclosures are the concall equivalent throughout - stated explicitly up front.
• Insider data: sourced solely from the MoatMap DART scrape per the gated-venue rule (zero transactions in 12 months).
• Buybacks: combined the MoatMap 90-day window (zero, consistent with the program ending Feb 26 2026) with external sources for the 2024 (₩2B) and 2025 (₩5B / 342k shares) programs.
• Section 13 omitted: no SemiAnalysis/Stratechery/MBI coverage exists for this name.
• Soft data points (exact 3-year DPS, FY2023 revenue, regional split) are flagged as approximate where the English-language record was incomplete; I did not fabricate precise figures.

Would you like me to save this as a .md file in the working directory?